CorMedix Inc.: Oppenheimer cuts target price to $13 from $15
CRMD•Oppenheimer cut its target price for CorMedix Inc. to $13 from $15.
Related News
Applied Materials: BofA Global Research cuts price objective to $520 from $650
AMAT•
Health in Tech Q3 2026 adjusted EBITDA swings to $3.9 million loss
HIT•
HDFC Bank board reappoints V. Srinivasa Rangan as executive director for one year
HDB•
Eagle Point Income Company Q3 net income $4.6 million
EIC•
SS Innovations International appoints Gary Lo as chief financial officer
SSII•